Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Comprehensive Loss

v3.23.1
Consolidated Statements of Comprehensive Loss - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Revenue from Contract with Customer [Abstract]    
Product Revenue
Product Cost of Sales
Gross Income
Administrative Expenses 5,520,150 6,420,092
Research and Development Expenses 9,067,422 6,745,104
Accretion of Debt Discount 608,460
Stock Based Compensation 695,191
Stock Option Modification Expenses 15,036,051
Loss from Operations (15,282,763) (28,809,707)
Other (Income) Expenses    
Interest and Dividend Income (83,991) (8,907)
(Gain)/Loss on Sales of Marketable Securities 5,964 (39,597)
Unrealized (Gain)/Loss on Marketable Securities (2,958) 42,793
Gain on Debt Forgiveness (180,257)
Uninsured Casualty Losses (4,442) 1,265,306
Total Other (Income) Expenses (85,427) 1,079,338
Loss Before Income Tax (15,197,336) (29,889,045)
Income Tax Benefit
Net Loss $ (15,197,336) $ (29,889,045)
Basic and Dilutive net loss per common share $ (0.39) $ (0.85)
Weighted average basic and diluted common shares outstanding 38,825,763 35,017,244